CorVel Corp. (CRVL) Stock Price & How to Invest

CorVel Corporation is a Nasdaq-listed provider of workers' compensation claims management and healthcare cost-containment services. It runs two reporting segments: Patient Management, which handles third-party claims administration, case management, and return-to-work services for self-insured employers and carriers, and Network Solutions, which covers medical bill review, PPO network access, pharmacy management, and, through the CERIS brand, payment integrity for commercial health payers. The company layers artificial intelligence, machine learning, and natural language processing over its proprietary CareMC platform (recently extended with a tool called CorVel Connected) to flag billing errors, route care, and compress the cost of an episode.

The investment picture is a compounder that lost its premium multiple. Fiscal 2026 (ended March 31, 2026) revenue rose ~7% to ~$959 million and diluted EPS rose ~17% to ~$2.14, with operating margin expanding about 1.4 points to ~14.9% and the balance sheet ending the year with ~$233 million in cash and no debt. Yet the stock fell from a 52-week high near ~$94 to roughly ~$61, because the market repriced growth: 7% top-line expansion is well below what CorVel's historical multiple assumed, and workers' compensation claim frequency has been declining for years as workplaces get safer and insurers cut rates. The bull framing rests on CERIS and payment integrity broadening the addressable market beyond workers' compensation; the bear framing is that a slow-growth services business without a dividend deserves the lower multiple it now carries.

The core end market is the central risk: workers' compensation claim frequency has trended down for years as workplaces automate and get safer, and soft premium rates squeeze what carriers and employers will pay for managed-care services. Growth has decelerated to roughly 7%, and the stock's ~43% decline over the past year reflects the market resetting expectations rather than any earnings miss, which means further deceleration could compress the multiple again. Competition is intense and much better capitalized, with Sedgwick, Enlyte, Gallagher Bassett, and Optum's workers' compensation units all bidding on overlapping mandates. CorVel is also mid-leadership-transition, with Sarah Scott stepping in as CEO and President effective July 1, 2026 and prior CEO Michael Combs moving to Executive Chair. Finally, the CERIS payment-integrity expansion puts CorVel into commercial health, where entrenched specialists such as Optum, Cotiviti, and Zelis already hold scale relationships.

We give no verdict on CorVel Corp.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. CERIS and commercial payment integrity. CERIS, CorVel's payment-integrity arm, targets commercial health payers rather than the workers' compensation pool, which is the company's main route to a larger addressable market.

The case against. The core end market is the central risk: workers' compensation claim frequency has trended down for years as workplaces automate and get safer, and soft premium rates squeeze what carriers and employers will pay for managed-care services.

Read the full bull and bear case on CRVL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CorVel Corp.'s investor relations page or your broker.

• Revenue (TTM, FY2026): ~$959M (+7% YoY)
• Diluted EPS (FY2026): ~$2.14 (+17% YoY)
• Net income (FY2026): ~$110M (+16% YoY)
• Operating margin (FY2026): ~14.9% (up ~1.4pp)
• Cash and debt: ~$233M cash, no debt
• Market cap / trailing P/E: ~$3.1B / ~28x

CorVel's fiscal year ends March 31, so the trailing figures above are fiscal 2026, with the first quarter of fiscal 2027 due in early August 2026. The trailing P/E near ~28x is a sharp step down from the premium multiple the stock carried through 2025, when shares traded as high as ~$94 against a 52-week low near ~$45. That reset happened while earnings grew, so the story now hinges on whether mid-single-digit revenue growth plus margin leverage and share repurchases is enough to re-rate the multiple.

Other names that sit close to CRVL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CRVL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CRVL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CRVL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CorVel is a quietly profitable niche compounder whose valuation reset in 2026, and the debate is whether CERIS and payment integrity can outgrow a slow-fading workers' compensation core.

Whether CRVL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRVL a buy or a sell?, and where the stock could go from here in the CRVL stock forecast.

For income investors, whether CRVL pays a dividend and how the payout looks is covered in does CRVL pay a dividend? And to weigh CRVL against a peer, read the full side-by-side comparisons: CRVL vs AJG.